Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376376 · ClinicalTrials.gov registry record · NA
Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli
A NA study, sponsored by Michigan State University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00376376 is a NA study that has completed, run by Michigan State University. The registered enrollment target is 10 participants.
The verdict
NCT00376376, a NA study, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Single-dose studies of a fluoroquinolone are indicative of their antimicrobial activity since little accumulation occurs with multiple doses. Single-dose studies have been utilized to determine drug concentrations and time kill activity in serum, urine, and respiratory tissues. The purpose of this study is to evaluate the Urine Bactericidal Activity (UBA) of levofloxacin (250, 500, 750, and 1000 mg) against FQ-resistant, ESBL positive E. coli isolates. In addition, a susceptibility breakpoint concentration in the urine can also be established for each dose of levofloxacin. Furthermore, urine concentrations and serum pharmacokinetic parameters of levofloxacin can be determined.
Interventions
- DRUG levofloxacin at 250, 500, 750, and 1000 mg doses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-09 |
| Est. Completion | 2006-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376376
The ClinicalTrials.gov registry entry for NCT00376376 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michigan State University, which has 120 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which levofloxacin at 250, 500, 750, and 1000 mg doses is the first listed.
NCT00376376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376376 about?
NCT00376376 is a clinical study titled "Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli". Single-dose studies of a fluoroquinolone are indicative of their antimicrobial activity since little accumulation occurs with multiple doses. Single-dose studies have been utilized to determine drug concentrations and time kill activity in serum, urine, and respiratory tissues. The purpose of this ...
What is the current status of trial NCT00376376?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2006-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00376376?
The interventions under investigation include: levofloxacin at 250, 500, 750, and 1000 mg doses (DRUG).
Who is sponsoring clinical trial NCT00376376?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.